West Pharmaceutical Services Inc. (WST) Position Raised by GHP Investment Advisors Inc.

GHP Investment Advisors Inc. raised its position in shares of West Pharmaceutical Services Inc. (NYSE:WST) by 1.1% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 40,761 shares of the medical instruments supplier’s stock after buying an additional 437 shares during the period. GHP Investment Advisors Inc. owned about 0.06% of West Pharmaceutical Services worth $3,327,000 at the end of the most recent reporting period.

Several other large investors have also made changes to their positions in WST. Advantus Capital Management Inc increased its stake in shares of West Pharmaceutical Services by 1.1% in the third quarter. Advantus Capital Management Inc now owns 8,950 shares of the medical instruments supplier’s stock worth $667,000 after buying an additional 100 shares in the last quarter. US Bancorp DE increased its stake in shares of West Pharmaceutical Services by 3.9% in the third quarter. US Bancorp DE now owns 2,921 shares of the medical instruments supplier’s stock worth $218,000 after buying an additional 110 shares in the last quarter. Suntrust Banks Inc. increased its stake in shares of West Pharmaceutical Services by 1.8% in the third quarter. Suntrust Banks Inc. now owns 9,149 shares of the medical instruments supplier’s stock worth $679,000 after buying an additional 166 shares in the last quarter. Ladenburg Thalmann Financial Services Inc. increased its stake in shares of West Pharmaceutical Services by 7.7% in the fourth quarter. Ladenburg Thalmann Financial Services Inc. now owns 2,945 shares of the medical instruments supplier’s stock worth $250,000 after buying an additional 210 shares in the last quarter. Finally, Capstone Asset Management Co. increased its stake in shares of West Pharmaceutical Services by 2.4% in the first quarter. Capstone Asset Management Co. now owns 10,160 shares of the medical instruments supplier’s stock worth $829,000 after buying an additional 234 shares in the last quarter. 90.31% of the stock is owned by institutional investors and hedge funds.

Institutional Ownership by Quarter for West Pharmaceutical Services (NYSE:WST)

Shares of West Pharmaceutical Services Inc. (NYSE:WST) traded up 0.24% during midday trading on Friday, hitting $95.31. The stock had a trading volume of 219,405 shares. West Pharmaceutical Services Inc. has a 12-month low of $70.17 and a 12-month high of $96.97. The company’s 50-day moving average price is $87.61 and its 200-day moving average price is $83.94. The firm has a market cap of $7.01 billion, a price-to-earnings ratio of 39.45 and a beta of 0.94.

West Pharmaceutical Services (NYSE:WST) last released its earnings results on Thursday, April 27th. The medical instruments supplier reported $0.81 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.55 by $0.26. The company had revenue of $387.70 million during the quarter, compared to analyst estimates of $380.42 million. West Pharmaceutical Services had a return on equity of 14.54% and a net margin of 9.27%. The company’s revenue for the quarter was up 7.1% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.53 earnings per share. Equities research analysts forecast that West Pharmaceutical Services Inc. will post $2.73 EPS for the current year.

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, August 2nd. Stockholders of record on Wednesday, July 19th will be issued a $0.13 dividend. The ex-dividend date is Monday, July 17th. This represents a $0.52 dividend on an annualized basis and a dividend yield of 0.55%. West Pharmaceutical Services’s payout ratio is currently 28.11%.

TRADEMARK VIOLATION WARNING: “West Pharmaceutical Services Inc. (WST) Position Raised by GHP Investment Advisors Inc.” was originally reported by Transcript Daily and is the sole property of of Transcript Daily. If you are viewing this piece on another domain, it was copied illegally and republished in violation of US and international trademark & copyright laws. The correct version of this piece can be read at https://transcriptdaily.com/2017/05/20/west-pharmaceutical-services-inc-wst-position-raised-by-ghp-investment-advisors-inc.html.

A number of equities research analysts have recently commented on the company. Zacks Investment Research raised West Pharmaceutical Services from a “sell” rating to a “hold” rating in a research report on Saturday, April 22nd. Jefferies Group LLC reaffirmed a “hold” rating and issued a $90.00 price objective (up previously from $82.00) on shares of West Pharmaceutical Services in a research report on Friday, April 28th.

In other news, CFO William J. Federici sold 54,996 shares of the stock in a transaction on Thursday, May 18th. The stock was sold at an average price of $95.45, for a total value of $5,249,368.20. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, VP Daniel Malone sold 4,124 shares of the stock in a transaction on Tuesday, May 2nd. The shares were sold at an average price of $93.31, for a total value of $384,810.44. The disclosure for this sale can be found here. 5.13% of the stock is owned by corporate insiders.

About West Pharmaceutical Services

West Pharmaceutical Services, Inc is a manufacturer of packaging components and delivery systems for injectable drugs and healthcare products. The Company’s products include vial containment solutions, prefillable systems, self-injection platforms, cartridge systems and components, reconstitution and transfer systems, intradermal delivery solutions, specialty components, and contract manufacturing and analytical services.

12 Month Chart for NYSE:WST

Receive News & Ratings for West Pharmaceutical Services Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for West Pharmaceutical Services Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply